News & Events about Vbi Vaccines Inc.
Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results PR Newswire DURHAM, N.C. and BEIJING, March 24, 2023 Company maintains priority focus on clinical programs to develop a...
Business Wire
3 months ago
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced interim data from the Phase 2 study evaluating the combination of VBI-2601 (BRII-179), VBIs HBV immunotherapeutic candidate, and...
Business Wire
6 months ago
The Coalition for Epidemic Preparedness Innovations (CEPI) is expanding its world-leading portfolio of potential variant-proof coronavirus vaccines in a deal with VBI Vaccines Inc. (Nasdaq: VBIV) to advance the development of multivalent coronavirus shots that could be deployed against COVID-19 as...
Business Wire
6 months ago
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that additional biomarker data from the Phase 1/2a study of VBI-1901, the Companys cancer vaccine immunotherapeutic candidate in...
Business Wire
7 months ago
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that its abstract highlighting data from the ongoing Phase 2a study of VBI-1901, the Companys cancer vaccine immunotherapeutic...